T Cell Immunotherapy News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected news for T Cell Immunotherapy, which is filed under Healthcare Topics. There are 156 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
8/10/2022 ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
In vitro study of the ELIAS Cancer Immunotherapy (ECI ¬AE ) showed personalized T cell immunotherapy initiated a significant immune response against target cancer cells. OLATHE, Kan. , Aug. 10, 2022 /PRNewswire/ -- ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI ¬AE ) at the 2022 ...
PR Newswire
5/24/2022 Cancer Cell Paper Identifies "Avidity Enhancement" As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia
... dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML) . AML poses significant clinical challenges due to its resistance ...
PR Newswire
5/7/2022 Life sciences news: Adaptive reveals data on Lyme disease test; mental health startup lands $10M
Provided by Geekwire Seattle Children's is partnering with Umoja Biopharma to test a new CAR T cell immunotherapy in patients with sarcoma, a form of bone cancer. (Seattle Children's Photo) Here's a rundown of the top life sciences and health news across the Pacific Northwest this week ...
MSN
5/5/2022 AlloVir Reports First Quarter 2022 Financial Results Business Wire
5/5/2022 AlloVir Reports First Quarter 2022 Financial Results | Business Wire Business Wire
5/2/2022 T cell Immunotherapy Market is Anticipated to Reach US$ 7648.9 Million, at a Robust CAGR of 15.7% Between 2020-2026 heraldkeeper.com
4/20/2022 FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients | Business Wire Business Wire
4/19/2022 Verismo Therapeutics Expands Scientific Team to Advance its KIR-CAR Platform for the Treatment of Solid Tumors PR Newswire
4/7/2022 Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board PR Newswire
4/7/2022 Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board Yahoo News
2/22/2022 Anocca Appoints New Senior Management Roles and Expands Scientific Teams PR Newswire
2/11/2022 AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference | Business Wire Business Wire
2/10/2022 AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook Business Wire
12/14/2021 Single-cell imaging of T cell immunotherapy responses in vivo - PubMed National Institutes of Health
12/1/2021 YESCARTA (axicabtagene ciloleucel) suspension [Kite Pharma, Inc.] National Institutes of Health
8/19/2021 Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma - Stocks News Feed stocksnewsfeed.com
8/19/2021 Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma Yahoo News
8/19/2021 Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma financialbuzz.com
8/19/2021 Bristol Myers Gets Conditional Marketing Authorization for Abecma - MarketWatch MarketWatch
8/19/2021 Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma bms.com
8/14/2021 Lonza and Sheba Medical Centre Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy textile-future.com
8/3/2021 TECARTUS (brexucabtagene autoleucel) suspension [Kite Pharma, Inc.] National Institutes of Health
7/28/2021 Doubling down with CAR-T cell cancer immunotherapy: a two-step recognition circuit enables discrimination between target antigen high and low cancer cells Nature
6/30/2021 Gilead's (GILD) Kite Announces Positive Data on Yescarta Yahoo News
6/30/2021 Gilead's (GILD) Kite Announces Positive Data on Yescarta MSN